Welcome to our dedicated page for TransCode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on TransCode Therapeutics stock.
TransCode Therapeutics, Inc. develops RNA and immuno-oncology therapeutics for high-risk and advanced cancers. News about RNAZ centers on its lead candidate TTX-MC138, an antagomiR targeting microRNA-10b, along with preclinical publications, IND-related clinical updates, research collaborations and sponsored research tied to RNA-targeted oncology.
Company updates also cover additions to its early-stage oncology pipeline, including adenovirus-based oncolytic immunotherapy candidates UIO-524, UIO-525 and UIO-526, as well as governance changes involving its board and scientific advisory structure. Capital-structure announcements, material agreements and operating or financial results are recurring disclosure themes for this clinical-stage biotechnology issuer.
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has priced its initial public offering (IPO) of 6,250,000 shares at $4.00 per share, aiming for gross proceeds of $25 million. The underwriters have a 45-day option to buy an additional 937,500 shares. Proceeds will fund the Phase 0 trial of lead candidate TTX-MC138, development of its drug portfolio, and general corporate purposes. Trading is set to begin on July 9, 2021, with closing expected on July 13, 2021. ThinkEquity manages the offering.